NCT02225366View on ClinicalTrials.gov

Intratumoral Injections of LL37 for Melanoma

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

July 8, 2015

Primary Completion Date

November 24, 2020

Study Completion Date

November 24, 2020

Conditions
Melanoma
Interventions
BIOLOGICAL

LL37

Starting dose 250 µg/tumor. The injections will be given every 7 days for up to 8 weeks.

OTHER

Photographs

Tumors measured and photographed one week before receiving LL37, and again at 4 weeks after LL37. Then photographs of the LL37 injected sites taken at 8 weeks.

Trial Locations (1)

77030

University of Texas MD Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER

NCT02225366 - Intratumoral Injections of LL37 for Melanoma | Biotech Hunter | Biotech Hunter